AI-SCREENDCM Decentralized Clinical Trial - Pilot Study
- Conditions
- Cardiomyopathy
- Interventions
- Diagnostic Test: KardiaRx ECG Screening
- Registration Number
- NCT06609174
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 250
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description First Degree Relative KardiaRx ECG Screening Subjects who are first-degree relatives of patients with DCM
- Primary Outcome Measures
Name Time Method Number of First-Degree Relatives to complete the AI-ECG Baseline Measured by the number of complete transmissions from the Kardia 6-lead device to the AI-ECG algorithm.
Number of First-Degree relatives to complete cardiac screening Baseline The following screening procedures will be considered a valid cardiac screening attempt:
* Scheduled or Completed TTE
* Scheduled or completed clinician visit for the purposes of generating a cardiac evaluation
- Secondary Outcome Measures
Name Time Method Number of subjects with an Left Ventricular Ejection Fraction ≤ 45% Baseline Left Ventricular Ejection Fraction will be determined by AI-ECG
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States